Nab-paclitaxel (Nab-P) is approved for the treatment of metastatic breast cancer (MBC) after first line therapy and when anthracyclines are not indicated. Clinical trials proved high efficacy and reduced toxicity of nab-P compared to standard taxanes. Real world data of nab-P in MBC, however, are still limited.
The prospective, multicenter, non-interventional NABUCCO study was designed to collect data on effectiveness including overall survival, safety, treatment patterns and quality of life (QoL) in patients (pts) with MBC in real world. QoL was assessed with the validated questionnaires Functional Assessment of Cancer Therapy-General (FACT-G) and the breast cancer and taxane specific modules (FACT-B and FACT-Taxane) at baseline (BL), 3, 6 months. Data were analyzed descriptively. Survival was analyzed with the Kaplan-Meier method.
697 of 705 pts with MBC enrolled at 128 sites in Germany from 4/2012 to 4/2015 were evaluable (median age 62.3 years (yrs) (min-max 29.2-89.3); age ≥65 yrs n = 291 (41.8%), ECOG 0/1 n = 628 (90.1%), prior taxanes n = 419 (60.1%)). 194 pts (27.8%) received 220-260 mg/m2 q3w, 491 pts (70.4%) received weekly nab-P at ≤ 150 mg/m2 (physician’s discretion; 1.7% other). Median overall survival (mOS, months [95% CI]) was 15.6 [14.2-17.2]. No difference was observed with regard to treatment pattern (15.1 [12.3-17.5] q3w vs 16.3 [14.4-18.5] weekly) and age (15.7 [14.0-18.1]
The NABUCCO study confirms survival data from clinical trials in real world without deteriorated global and breast cancer related QoL.
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.